In a regulatory filing, Cytokinetics (CYTK) president and CEO Robert Blum disclosed the sale of 15,000 common shares of the company on March 31 at a price of $40.75 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics announces launch of EARTH-HCM
- Promising Potential of Cytokinetics’ Aficamten in Cardiac Treatment Drives Buy Recommendation
- Cytokinetics’ data supports aficamten’s potential, says H.C. Wainwright
- Cytokinetics announces presentations as ACC Scientific Session & Expo
- Promising Progress and Positive Outlook for Cytokinetics’ Aficamten in oHCM Treatment